{"id":48,"count":6,"description":"<div class=\"scroll-box\">\r\n<h2 style=\"text-align: center\">Istra\u017eivanje GLP-1 peptida: Primjena u istra\u017eivanju metabolizma i regulacije apetita<\/h2>\r\n<em>GLP-1 peptidi su kategorija istra\u017eiva\u010dkih spojeva koji se prou\u010davaju zbog svojih u\u010dinaka na regulaciju \u0161e\u0107era u krvi, suzbijanje apetita i metaboli\u010dku ravnote\u017eu. Ovi peptidi opona\u0161aju ili poja\u010davaju djelovanje glukagonu sli\u010dnog peptida-1, hormona koji ima sredi\u0161nju ulogu u homeostazi glukoze i unosu energije. U laboratorijskim uvjetima, GLP-1 peptidi se obi\u010dno istra\u017euju zbog svog potencijala u modelima pretilosti, dijabetesa tipa 2 i kontrole tjelesne te\u017eine. <\/em>\r\n\r\nGLP-1 peptides are a class of research compounds that mimic or enhance the activity of glucagon-like peptide-1, a hormone involved in appetite control, insulin secretion, and glucose metabolism. In scientific studies, these peptides are explored for their ability to suppress hunger, promote fat loss, and regulate blood sugar levels, making them a major focus in research targeting obesity, type 2 diabetes, and other metabolic disorders.\r\n\r\nGLP-1 receptor agonists work by activating incretin pathways (GLP-1, GIP, and glucagon receptors), which collectively help improve insulin sensitivity, slow gastric emptying, reduce food intake, and increase metabolic expenditure. More advanced compounds in this class also target multiple receptors to enhance metabolic effects, offering new possibilities for studying complex weight-related mechanisms in lab settings.\r\n\r\n<em><strong>Odricanje odgovornosti: <\/strong>Svi ovdje spomenuti GLP-1 peptidi namijenjeni su isklju\u010divo laboratorijskim istra\u017eivanjima. Svi spomenuti ishodi vezani uz ljude temelje se isklju\u010divo na nalazima iz \u017eivotinjskih modela ili klini\u010dkih podataka te se ne smiju tuma\u010diti kao medicinski savjet ili terapeutske preporuke.<\/em>\r\n<h2>\u0160to su agonisti GLP-1 receptorskih peptida?<\/h2>\r\nGLP-1 receptor agonist peptides are synthetic compounds designed to replicate or enhance the effects of glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut after eating. In research settings, GLP-1 is known for its ability to stimulate insulin secretion, suppress appetite, slow gastric emptying, and regulate blood sugar. However, the natural hormone breaks down quickly in the body, prompting the development of longer-lasting analogs for laboratory use.\r\n\r\nModern GLP-1 peptides are engineered for increased stability and often include multi-receptor activity. In addition to GLP-1 activation, some of these peptides also target:\r\n<ul>\r\n \t<li><strong>GIP (glukoza-ovisni inzulinotropni polipeptid):<\/strong> Pobolj\u0161ava lu\u010denje inzulina i utje\u010de na metabolizam masti<\/li>\r\n \t<li><strong>Glukagonski receptori:<\/strong> Poti\u010de oksidaciju masti, termogenezu i potro\u0161nju energije<\/li>\r\n<\/ul>\r\nOvi kombinirani u\u010dinci \u010dine agoniste GLP-1 receptora vrijednima u pretklini\u010dkim istra\u017eiva\u010dkim modelima usmjerenima na:\r\n<ul>\r\n \t<li>Gubitak te\u017eine i suzbijanje apetita<\/li>\r\n \t<li>Pretilost i metaboli\u010dki sindrom<\/li>\r\n \t<li>Inzulinska rezistencija i homeostaza glukoze<\/li>\r\n \t<li>Istra\u017eivanja masnog tkiva i energetske ravnote\u017ee<\/li>\r\n<\/ul>\r\nPeptidi kao \u0161to su semaglutid, tirzepatid i retatrutid obi\u010dno se koriste u ovoj istra\u017eiva\u010dkoj kategoriji zbog svojih sna\u017enih metaboli\u010dkih u\u010dinaka i u\u010dinaka smanjenja tjelesne te\u017eine.\r\n<h2>Mehanizmi djelovanja GLP-1 peptida<\/h2>\r\nGLP-1 receptor agonist peptides work by mimicking or enhancing natural gut hormones that regulate hunger, insulin release, and energy metabolism. Each peptide in this category acts on different combinations of receptors to drive metabolic effects. Here's a breakdown of the mechanisms by individual peptide:\r\n\r\n<strong>Semaglutid<\/strong>\r\n<ul>\r\n \t<li>Kao agonist GLP-1 receptora, semaglutid opona\u0161a prirodne inkretinske hormone.<\/li>\r\n \t<li>Usporava pra\u017enjenje \u017eeluca, \u010dime se produljuje osje\u0107aj sitosti i smanjuje unos kalorija.<\/li>\r\n \t<li>Poja\u010dava izlu\u010divanje inzulin u odgovoru na glukozu i sni\u017eava razinu \u0161e\u0107era u krvi.<\/li>\r\n \t<li>Njegov dizajn s produljenim djelovanjem podr\u017eava doziranje jednom tjedno u istra\u017eiva\u010dkim modelima, odr\u017eavaju\u0107i stabilnu aktivaciju receptora tijekom vremena.<\/li>\r\n<\/ul>\r\n<strong>Tirzepatid<\/strong>\r\n<ul>\r\n \t<li>Dvostruki agonist i GLP-1 i GIP receptora (inzulinotropni polipeptid ovisan o glukozi).<\/li>\r\n \t<li>Pobolj\u0161ava osjetljivost na inzulin i izlu\u010divanje inzulina uz istovremenu modulaciju razine glukagona.<\/li>\r\n \t<li>Sna\u017eno potiskuje apetit i pobolj\u0161ava glikemijsku kontrolu, \u0161to dovodi do zna\u010dajnog gubitka te\u017eine.<\/li>\r\n \t<li>U klini\u010dkim ispitivanjima SURPASS, tirzepatid je nadma\u0161io semaglutid u smanjenju tjelesne te\u017eine i glukoze u krvi.<\/li>\r\n<\/ul>\r\n<strong>Retatrutid<\/strong>\r\n<ul>\r\n \t<li>Trostruki agonist receptora usmjeren na GLP-1, GIP i glukagonske receptore.<\/li>\r\n \t<li>Aktivira putove glukagona kako bi pove\u0107ao potro\u0161nju energije i bazalni metabolizam.<\/li>\r\n \t<li>Poti\u010de lipolizu i oksidaciju masti, \u0161to ga \u010dini jednim od najmo\u0107nijih peptida prou\u010davanih za smanjenje tjelesne masti.<\/li>\r\n \t<li>Rani klini\u010dki ispitivanja na ljudima pokazuju ve\u0107i gubitak te\u017eine nego drugi spojevi na bazi GLP-1.<\/li>\r\n<\/ul>\r\nZajedno, ovi peptidi predstavljaju mo\u0107nu klasu metaboli\u010dkih regulatora u laboratorijskim studijama, nude\u0107i uvid u kontrolu apetita, dinamiku inzulin\u00e2 i energetsku ravnote\u017eu.\r\n<h2>Istra\u017eivanja i klini\u010dki nalazi<\/h2>\r\nGLP-1 peptidi poput semaglutida, tirzepatida i retatrutida preoblikovali su metaboli\u010dka istra\u017eivanja zbog svojih sna\u017enih u\u010dinaka na gubitak te\u017eine, regulaciju apetita i kontrolu glukoze. Svaki je prou\u010davan u opse\u017enim klini\u010dkim i laboratorijskim ispitivanjima, uz dosljedno sna\u017ene ishode:\r\n<h3>Semaglutid<\/h3>\r\n<ul>\r\n \t<li>U klini\u010dkim ispitivanjima STEP, pretili sudionici bez dijabetesa izgubili su u prosjeku ~15% tjelesne te\u017eine tijekom 68 tjedana.<\/li>\r\n \t<li>Zna\u010dajna smanjenja zabilje\u017eena su i u opsegu struka, razini inzulina nata\u0161te i upalnim biomarkerima.<\/li>\r\n \t<li>Sudionici su izvijestili o potiskivanju apetita unutar nekoliko dana, \u0161to je pobolj\u0161alo pridr\u017eavanje dugoro\u010dnih istra\u017eiva\u010dkih protokola.<\/li>\r\n<\/ul>\r\n<h3>Tirzepatid<\/h3>\r\n<ul>\r\n \t<li>Istra\u017eivanje SURMOUNT-1 pokazalo je gubitak tjelesne te\u017eine od ~22,51 TP3T tijekom 72 tjedna.<\/li>\r\n \t<li>Tirzepatid je tako\u0111er pobolj\u0161ao razine HbA1c, osjetljivost na inzulin i lipidni profil.<\/li>\r\n \t<li>Njezino dvojno GIP i GLP-1 djelovanje u\u010dinilo ju je superiornijom u odnosu na same GLP-1 agoniste u izravnim klini\u010dkim ispitivanjima.<\/li>\r\n \t<li>Istra\u017eivanja pokazuju dobrobiti u dijabeti\u010dkim i nedijabeti\u010dkim metaboli\u010dkim modelima.<\/li>\r\n<\/ul>\r\n<h3>Retatrutid<\/h3>\r\n<ul>\r\n \t<li>Istra\u017eivanje II. faze (2023.) pokazalo je gubitak masne mase do 24,21 TP3T kod pretilih sudionika, \u0161to je do danas najve\u0107i postotak zabilje\u017een u klasi inkretina.<\/li>\r\n \t<li>Kroz aktivaciju glukagonskog receptora, pove\u0107ala je potro\u0161nju energije i oksidaciju masti iznad samih mehanizama GLP-1\/GIP-a.<\/li>\r\n \t<li>Tako\u0111er su pokazane koristi u krvnom tlaku, trigliceridima i jetrenoj masti.<\/li>\r\n<\/ul>\r\n<strong>Ukupni uvidi<\/strong>\r\n\r\nSva tri peptida dosljedno pokazuju:\r\n<ul>\r\n \t<li>Brzo suzbijanje apetita<\/li>\r\n \t<li>Smanjena masna masa, opseg struka i inzulin nata\u0161te<\/li>\r\n \t<li>Pobolj\u0161ani kardiometaboli\u010dki markeri (kolesterol, krvni tlak, CRP)<\/li>\r\n \t<li>Duga poluvremena raspada \u010dine ih idealnima za tjedno ili dvotjedno doziranje u istra\u017eivanjima<\/li>\r\n<\/ul>\r\nOvi su nalazi u\u010dvrstili agoniste GLP-1 receptora kao temeljne spojeve u istra\u017eivanju pretilosti i metabolizma.\r\n<h2>Uvidi u sigurnost i propise<\/h2>\r\nGLP-1 peptide research continues to evolve, with several compounds already approved for clinical use and others in advanced trial phases:\r\n\r\nSemaglutide is FDA-approved for both type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It is widely studied in metabolic models and has a well-documented safety profile in both diabetic and non-diabetic populations.\r\n\r\nTirzepatide, a dual GLP-1\/GIP agonist, is also FDA-approved for type 2 diabetes (as Mounjaro) and is under review for obesity-related approvals, following positive SURMOUNT trial data.\r\n\r\nRetatrutide, the triple agonist (GLP-1, GIP, glucagon), remains investigational but has shown groundbreaking results in Phase II trials, with potential to become a new class leader in fat loss and metabolic support research.\r\n\r\n<strong>\u010cesto uo\u010deni u\u010dinci u istra\u017eivanjima uklju\u010duju:<\/strong>\r\n<ul>\r\n \t<li>Mu\u010dnina<\/li>\r\n \t<li>Zatvor<\/li>\r\n \t<li>Smanjenje apetita<\/li>\r\n \t<li>Ovi su obi\u010dno ovisni o dozi i smanjuju se tijekom vremena u dugotrajnim studijama.<\/li>\r\n<\/ul>\r\n<strong>Smjernice za upotrebu:<\/strong>\r\n<ul>\r\n \t<li>Primijeniti u kontroliranim laboratorijskim uvjetima usmjerenima na pretilost, inzulinsku rezistenciju ili energetski metabolizam.<\/li>\r\n \t<li>Odr\u017eavajte sterilnu tehniku, skladi\u0161tenje u hladnom lencu i dokumentaciju protokola radi ponovljivosti.<\/li>\r\n<\/ul>\r\n<strong>Va\u017ena podsjetnica:<\/strong>\r\n\r\nSvi opona\u0161eni peptidi namijenjeni su isklju\u010divo za laboratorijska istra\u017eivanja. Nisu odobreni za primjenu na ljudima, osim u kontekstu reguliranih klini\u010dkih ispitivanja ili lije\u010denja na recept.\r\n<h2>Najbolji GLP-1 peptidi za istra\u017eivanje<\/h2>\r\nGLP-1 peptidi su revolucionirali istra\u017eivanja metabolizma i pretilosti. Sljede\u0107i peptid se isti\u010de svojom dobro dokumentiranom u\u010dinkovito\u0161\u0107u u pretklini\u010dkim i klini\u010dkim modelima:\r\n<ul>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/hr\/product\/buy-semaglutide-5mg\/\"><strong>Semaglutid<\/strong><\/a> \u2013 Agonist GLP-1 receptora, opse\u017eno istra\u017een i poznat po svojoj ulozi u suzbijanju apetita, regulaciji glukoze i smanjenju masne mase. U dugoro\u010dnim studijama o pretilosti pokazalo je dosljedan gubitak tjelesne te\u017eine od otprilike 151 TP3T.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/hr\/product\/buy-tirzepatide-5mg\/\"><strong>Tirzepatid<\/strong><\/a> \u2013 Dvostruki agonist GLP-1\/GIP koji pove\u0107ava osjetljivost na inzulin i smanjuje tjelesnu te\u017einu \u010dak u\u010dinkovitije od semaglutida. Klini\u010dka ispitivanja poput SURMOUNT-1 izvijestila su o prosje\u010dnom gubitku te\u017eine od 22,51 TP3T kod ispitanika na lije\u010denju.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/hr\/product\/buy-retatrutide-5mg\/\"><strong>Retatrutid<\/strong><\/a> \u2013 Trostruki agonist nove generacije koji cilja GLP-1, GIP i glukagon receptore. Rana ispitivanja pokazuju gubitak masno\u0107e do 24,21 TP3T, \u0161to ga \u010dini jednim od najsna\u017enijih peptida u trenuta\u010dnim istra\u017eivanjima pretilosti.<\/li>\r\n<\/ul>\r\n<h2>Laboratorijska upotreba i rekonstitucija<\/h2>\r\nGLP-1 peptid poput semaglutida, tirzepatida i retatrutida moraju biti pravilno rekonstituirani i njima se mora rukovati u sterilnim laboratorijskim uvjetima kako bi se odr\u017eala stabilnost i to\u010dnost u istra\u017eivanju.\r\n\r\n<strong>Rekonstitucija<\/strong>Ve\u0107ina GLP-1 peptida mo\u017ee se rekonstituirati pomo\u0107u bakteriostatske vode ili sterilne fiziolo\u0161ke otopine. Polako ubrizgajte otapalo niz unutarnju stijenku bo\u010dice kako biste izbjegli pjenjenje i nje\u017eno vrtite dok se potpuno ne otopi.\r\n\r\n<strong>Skladi\u0161tenje<\/strong>:\r\n<ul>\r\n \t<li>Liofilizirani peptidi mogu se \u010duvati na sobnoj temperaturi i za\u0161ti\u0107eni od svjetlosti.<\/li>\r\n \t<li>Rekonstituirani peptidi ostaju stabilni 30-60+ dana kada se \u010duvaju u hladnjaku na 2\u20138 \u00b0C.<\/li>\r\n<\/ul>\r\n<strong>Doziranje u pretklini\u010dkim modelima:<\/strong>\r\n\r\nStandardno doziranje se kre\u0107e od 0,01\u20130,2 mg\/kg kod mi\u0161eva ili \u0161takora, ovisno o eksperimentalnoj postavi i istra\u017eiva\u010dkim ciljevima.\r\n<h3>Uobi\u010dajeni istra\u017eiva\u010dki ciljevi:<\/h3>\r\n<ul>\r\n \t<li>Pra\u0107enje tjelesne te\u017eine tijekom vremena<\/li>\r\n \t<li>Suzbijanje apetita i pra\u0107enje unosa hrane<\/li>\r\n \t<li>Test optere\u0107enja glukozom (GTT)<\/li>\r\n \t<li>Analiza mase i sastiva masnog jastu\u010di\u0107a<\/li>\r\n \t<li>Aktivnost hormona inkretina, uklju\u010duju\u0107i testove za inzulin, GLP-1, GIP i glukagon<\/li>\r\n<\/ul>\r\nOvi peptidi su namijenjeni isklju\u010divo za laboratorijska istra\u017eivanja, i svako rukovanje treba pratiti eti\u010dke protokole i najbolje sterilne prakse.\r\n<h2>\u010cesta pitanja<\/h2>\r\n<h3>Koji GLP-1 peptid proizvodi najve\u0107i gubitak masti?<\/h3>\r\nRetatrutid je u ranim klini\u010dkim ispitivanjima pokazao najzna\u010dajniji gubitak tjelesne te\u017eine (~24%).\r\n<h3>Mogu li se peptidi kombinirati za bolje rezultate?<\/h3>\r\nObi\u010dno ne. Retatrutid ve\u0107 aktivira GLP-1, GIP i glukagonske receptore, \u0161to dodatno kombiniranje \u010dini nepotrebnim.\r\n<h3>\u0160to trebam u\u010diniti ako se peptid ne otopi u potpunosti?<\/h3>\r\nLagano vrtlo\u017eite bo\u010dicu, nemojte je tressti. Blago zagrijavanje (u vodenoj kupelji na 37 \u00b0C) mo\u017ee pomo\u0107i pri otapanju.\r\n<h3>Postoje li razlike u afinitetu prema receptorima me\u0111u tim peptidima?<\/h3>\r\nYes. Semaglutide selectively targets GLP-1 receptors, while Tirzepatide and Retatrutide act on multiple receptors for a broader effect.\r\n\r\nTo finish up, GLP-1 peptides represent a leading edge in metabolic research, offering compelling avenues to study fat loss, insulin regulation, and appetite suppression. Peptides such as Semaglutide, Tirzepatide, and Retatrutide have shown significant effects in both preclinical and clinical models, making them valuable tools for obesity and diabetes-related investigations.\r\n\r\nExplore the full GLP-1 peptide catalog at CellPeptides to support your next metabolic research project.\r\n\r\n<\/div>","link":"https:\/\/cellpeptides.com\/hr\/purpose\/glp-1-peptides\/","name":"GLP-1 istra\u017eiva\u010dki peptidi","slug":"glp-1-peptides","taxonomy":"product_cat","parent":0,"meta":[],"menu_order":0,"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides<\/title>\n<meta name=\"description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cellpeptides.com\/hr\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:locale\" content=\"hr_HR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\" \/>\n<meta property=\"og:description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cellpeptides.com\/hr\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:site_name\" content=\"CellPeptides\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"CollectionPage\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"url\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"name\":\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\",\"isPartOf\":{\"@id\":\"https:\/\/cellpeptides.com\/#website\"},\"description\":\"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU\",\"breadcrumb\":{\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\"},\"inLanguage\":\"hr\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cellpeptides.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Research Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cellpeptides.com\/#website\",\"url\":\"https:\/\/cellpeptides.com\/\",\"name\":\"CellPeptides\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cellpeptides.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cellpeptides.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"hr\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cellpeptides.com\/#organization\",\"name\":\"CellPeptides\",\"url\":\"https:\/\/cellpeptides.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"hr\",\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"contentUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"width\":697,\"height\":152,\"caption\":\"CellPeptides\"},\"image\":{\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kupite GLP-1 peptide za metaboli\u010dke studije (in-vitro) - CellPeptides","description":"Kupite GLP-1 agoniste receptora za istra\u017eivanje apetita, glukoze i metabolizma \u2013 Semaglutid, Tirzepatid, Retatrutid. Brza dostava u SAD-u i EU.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cellpeptides.com\/hr\/purpose\/glp-1-peptides\/","og_locale":"hr_HR","og_type":"article","og_title":"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides","og_description":"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU","og_url":"https:\/\/cellpeptides.com\/hr\/purpose\/glp-1-peptides\/","og_site_name":"CellPeptides","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"CollectionPage","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","url":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","name":"Kupite GLP-1 peptide za metaboli\u010dke studije (in-vitro) - CellPeptides","isPartOf":{"@id":"https:\/\/cellpeptides.com\/#website"},"description":"Kupite GLP-1 agoniste receptora za istra\u017eivanje apetita, glukoze i metabolizma \u2013 Semaglutid, Tirzepatid, Retatrutid. Brza dostava u SAD-u i EU.","breadcrumb":{"@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb"},"inLanguage":"hr"},{"@type":"BreadcrumbList","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cellpeptides.com\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Research Peptides"}]},{"@type":"WebSite","@id":"https:\/\/cellpeptides.com\/#website","url":"https:\/\/cellpeptides.com\/","name":"CellPeptides","description":"","publisher":{"@id":"https:\/\/cellpeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cellpeptides.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"hr"},{"@type":"Organization","@id":"https:\/\/cellpeptides.com\/#organization","name":"CellPeptides","url":"https:\/\/cellpeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"hr","@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","contentUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","width":697,"height":152,"caption":"CellPeptides"},"image":{"@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cellpeptides.com\/hr\/wp-json\/wp\/v2\/product_cat\/48","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cellpeptides.com\/hr\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/cellpeptides.com\/hr\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"wp:post_type":[{"href":"https:\/\/cellpeptides.com\/hr\/wp-json\/wp\/v2\/product?product_cat=48"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}